13 research outputs found
Intracarotid administration of human bone marrow mononuclear cells in rat photothrombotic ischemia
Background: Increasing evidence suggests that cell therapy improves functional recovery in experimental models of stroke and myocardial infarction. So far only small pilot trials tested the effects of cell therapy in stroke patients, whereas large clinical trials were conducted in patients with ischemic heart disease. To investigate the therapeutic benefit of cell therapy to improve the recovery after stroke, we determined the efficacy of bone marrow derived mononuclear cells, which were shown to improve the recovery in experimental and clinical acute myocardial infarction studies, in a rat stroke model. Methods: Adult male Wistar rats were randomly assigned to receive either five million human bone marrow mononuclear cells (hBMC) or placebo intraarterially 3 days after photothrombotic ischemia. For immunosuppression the animals received daily injections of cyclosporine throughout the experiment, commencing 24 hours before the cell transplantation. A battery of behavioural tests was performed before and up to 4 weeks after ischemia. Results: Body temperature and body weight revealed no difference between groups. Neurological deficits measured by the Rotarod test, the adhesive-removal test and the cylinder test were not improved by hBMC transplantation compared to placebo. Conclusions: This study demonstrates that hBMC do not improve functional recovery when transplanted intraaterially 3 days after the onset of focal cerebral ischemia. A possible reason for the failed neurological improvement after cell therapy might be the delayed treatment initiation compared to other experimental stroke studies that showed efficacy of bone marrow mononuclear cells
Downregulation of ETS Rescues Diabetes-Induced Reduction of Endothelial Progenitor Cells
Transplantation of vasculogenic progenitor cells (VPC) improves neovascularization after ischemia. However, patients with type 2 diabetes mellitus show a reduced VPC number and impaired functional activity. Previously, we demonstrated that p38 kinase inhibition prevents the negative effects of glucose on VPC number by increasing proliferation and differentiation towards the endothelial lineage in vitro. Moreover, the functional capacity of progenitor cells is reduced in a mouse model of metabolic syndrome including type 2 diabetes (Lepr(db)) in vivo.The aim of this study was to elucidate the underlying signalling mechanisms in vitro and in vivo. Therefore, we performed DNA-protein binding arrays in the bone marrow of mice with metabolic syndrome, in blood-derived progenitor cells of diabetic patients as well as in VPC ex vivo treated with high levels of glucose. The transcriptional activation of ETS transcription factors was increased in all samples analyzed. Downregulation of ETS1 expression by siRNA abrogated the reduction of VPC number induced by high-glucose treatment. In addition, we observed a concomitant suppression of the non-endothelial ETS-target genes matrix metalloproteinase 9 (MMP9) and CD115 upon short term lentiviral delivery of ETS-specific shRNAs. Long term inhibition of ETS expression by lentiviral infection increased the number of cells with the endothelial markers CD144 and CD105.These data demonstrate that diabetes leads to dysregulated activation of ETS, which blocks the functional activity of progenitor cells and their commitment towards the endothelial cell lineage
Patatinâlike phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events
Single nucleotide polymorphism (SNP) rs738409 C>G in the patatinâlike phospholipase domain containing 3 (PNPLA3) gene results in an amino acid exchange from isoleucin to methionine at position I148M of PNPLA3. The expression of this lossâofâfunction mutation leads to impaired hepatocellular triglyceride hydrolysis and is associated with the development of liver steatosis, fibrosis, and hepatocellular carcinoma. In contrast to these wellâestablished associations, the relationship of the PNPLA3 rs738409 variant with other metabolic traits is incompletely understood. We therefore assessed the association of the PNPLA3 rs738409 genotype with relevant metabolic traits in a prospective study of patients at high risk for cardiovascular events, i.e., patients undergoing coronary angiography. In a total of 270 patients, known associations of the PNPLA3 rs738409 GG genotype with nonalcoholic steatohepatitis and liver fibrosis were confirmed. In addition, we found an association of the PNPLA3 rs738409 G allele with the presence of diabetes (22% versus 28% versus 58% for CC versus CG versus GG genotype, respectively; P = 0.02). In contrast to its association with nonalcoholic fatty liver disease, liver fibrosis, and diabetes, the minor G allele of PNPLA3 rs738409 was inversely associated with total serum cholesterol and lowâdensity lipoprotein serum levels (P = 0.003 and P = 0.02, respectively). Finally, there was a trend toward an inverse association between the presence of the PNPLA3 rs738409 G allele and significant coronary heart disease. Comparable trends were observed for the transmembrane 6 superfamily member 2 (TM6SF2) 167 K variant, but the sample size was too small to evaluate this rarer variant. Conclusion: The PNPLA3 rs738409 G allele is associated with liver disease but also with a relatively benign cardiovascular risk profile
ETS-DNA-protein binding activity in BMC of Lepr<sup>db</sup> mice.
<p>DNA-binding activity of ETS family proteins in BMC of Lepr<sup>db</sup> mice and their age-matched littermates was analyzed by the use of precoated membranes (Panomics). In all cases 25 ”g of nuclear extracts were used. Representative membranes of nâ=â3 experiments are shown.</p
ETS in VPC of subjects with type 2 diabetes.
<p>DNA-binding activity of different transcription factors in ex vivo cultivated VPC of healthy controls and patients with type 2 diabetes was analyzed by the use of precoated membranes (Panomics). In all cases 25 ”g of nuclear extracts were used. Representative membranes of nâ=â3 experiments are shown.</p
ETS1 knockdown counteracts high-glucose induced reduction of VPC numbers.
<p>Mononuclear cells were transfected with ETS1-specific siRNA (ets1), a scrambled control (scr) at day 0 or left untransfected and stimulated with glucose. After 3 days of culture, VPC were stained and counted by independent investigators (left side). Data are mean±SEM of nâ„6; *p<0.05 vs. control. ETS1 protein expression was examined by immunoblot analysis (right side). Actin was used as loading control.</p
ETS-family DNA-binding activity in VPC after ex vivo glucose stimulation.
<p>Mononuclear cells were cultivated in EBM as described in the presence or absence of 15 mM glucose. DNA binding of different transcription factors was analyzed by the use of precoated membranes (Panomics). In all cases 25 ”g of nuclear extracts were used. Representative membranes of nâ=â3 experiments are shown, *p<0.05 vs. control.</p
ETS knockdown suppresses expression of non-endothelial ETS target genes and induces CD105 and CD144.
<p>Mononuclear cells were infected with lentiviruses expressing shRNAs targeting ETS1 (ets1) or ETS1 and ETS2 (ets1/2) or the corresponding scrambled shRNA controls (scr1, scr1/2). (A+B) After 4 days of culture RNA was prepared, and real-time RT-PCR was performed. Expression was normalized to 18S RNA and is shown relative to RNA isolated from cells transduced with a virus expressing the corresponding scrambled shRNA (scr). (A) ets1 knockdown, (B) ets1/2 knockdown. (C) After 12 days of culture, adherent VPC were stained with CD105 and CD144 antibodies and positive cells were counted. The upper part shows representative images, the lower part shows the quantification of the data of nâ=â4 experiments. Data are mean±SEM. *p<0.05 vs. scr, **p<0.05 vs. ets1.</p
Bone marrow and plasma FGFâ23 in heart failure patients: novel insights into the heartâbone axis
Aims: Fibroblast growth factor 23 (FGFâ23) is known to be elevated in patients with congestive heart failure (CHF). As FGFâ23 is expressed in the bone but can also be expressed in the myocardium, the origin of serum FGFâ23 in CHF remains unclear. It is also unclear if FGFâ23 expressed in the bone is associated with outcome in CHF. The aim of the present study was to investigate FGFâ23 levels measured in bone marrow plasma (FGFâ23âBM) and in peripheral blood (FGFâ23âP) in CHF patients to gain further insights into the heartâbone axis of FGFâ23 expression. We also investigated possible associations between FGFâ23âBM as well as FGFâ23âP and outcome in CHF patients.
Methods and results: We determined FGFâ23âP and FGFâ23âBM levels in 203 CHF patients (85% male, mean age 61.3 years) with a left ventricular ejection fraction (LVEF) â€45% and compared them with those of 48 healthy controls (48% male, mean age 39.2 years). We investigated the association between FGFâ23âBM and FGFâ23âP with allâcause mortality in CHF patients, 32 events, median followâup 1673 days, interquartile range [923, 1828]. FGFâ23âP (median 60.3 vs. 22.0 RU/mL, P < 0.001) and FGFâ23âBM (median 130.7 vs. 93.1 RU/mL, P < 0.001) levels were higher in CHF patients compared with healthy controls. FGFâ23âBM levels were significantly higher than FGFâ23âP levels in both CHF patients and in healthy controls (P < 0.001). FGFâ23âP and FGFâ23âBM correlated significantly with LVEF (r = â0.37 and r = â0.33, respectively), N terminal pro brain natriuretic peptide levels (r = 0.57 and r = 0.6, respectively), New York Heart Association status (r = 0.28 and r = 0.25, respectively), and estimated glomerular filtration rate (r = â0.43 and r = â0.41, respectively) (P for all <0.001) and were independently associated with allâcause mortality in CHF patients after adjustment for LVEF, estimated glomerular filtration rate, New York Heart Association status, and N terminal pro brain natriuretic peptide, hazard ratio 2.71 [confidence interval: 1.18â6.20], P = 0.018, and hazard ratio 2.80 [confidence interval: 1.19â6.57], P = 0.018, respectively.
Conclusions: In CHF patients, FGFâ23 is elevated in bone marrow plasma and is independently associated with heart failure severity and allâcause mortality. The failing heart seems to interact via FGFâ23 within a heartâbone axis
Bone marrow and plasma FGFâ23 in heart failure patients : novel insights into the heartâbone axis
Aims: Fibroblast growth factor 23 (FGFâ23) is known to be elevated in patients with congestive heart failure (CHF). As FGFâ23 is expressed in the bone but can also be expressed in the myocardium, the origin of serum FGFâ23 in CHF remains unclear. It is also unclear if FGFâ23 expressed in the bone is associated with outcome in CHF. The aim of the present study was to investigate FGFâ23 levels measured in bone marrow plasma (FGFâ23âBM) and in peripheral blood (FGFâ23âP) in CHF patients to gain further insights into the heartâbone axis of FGFâ23 expression. We also investigated possible associations between FGFâ23âBM as well as FGFâ23âP and outcome in CHF patients.
Methods and results: We determined FGFâ23âP and FGFâ23âBM levels in 203 CHF patients (85% male, mean age 61.3 years) with a left ventricular ejection fraction (LVEF) â€45% and compared them with those of 48 healthy controls (48% male, mean age 39.2 years). We investigated the association between FGFâ23âBM and FGFâ23âP with allâcause mortality in CHF patients, 32 events, median followâup 1673 days, interquartile range [923, 1828]. FGFâ23âP (median 60.3 vs. 22.0 RU/mL, P < 0.001) and FGFâ23âBM (median 130.7 vs. 93.1 RU/mL, P < 0.001) levels were higher in CHF patients compared with healthy controls. FGFâ23âBM levels were significantly higher than FGFâ23âP levels in both CHF patients and in healthy controls (P < 0.001). FGFâ23âP and FGFâ23âBM correlated significantly with LVEF (r = â0.37 and r = â0.33, respectively), N terminal pro brain natriuretic peptide levels (r = 0.57 and r = 0.6, respectively), New York Heart Association status (r = 0.28 and r = 0.25, respectively), and estimated glomerular filtration rate (r = â0.43 and r = â0.41, respectively) (P for all <0.001) and were independently associated with allâcause mortality in CHF patients after adjustment for LVEF, estimated glomerular filtration rate, New York Heart Association status, and N terminal pro brain natriuretic peptide, hazard ratio 2.71 [confidence interval: 1.18â6.20], P = 0.018, and hazard ratio 2.80 [confidence interval: 1.19â6.57], P = 0.018, respectively.
Conclusions: In CHF patients, FGFâ23 is elevated in bone marrow plasma and is independently associated with heart failure severity and allâcause mortality. The failing heart seems to interact via FGFâ23 within a heartâbone axis